Navigation Links
Stop-Smoking Vaccine in the Works

Researchers move closer to a shot for kicking nicotine addiction

MONDAY, Oct. 12 (HealthDay News) -- The National Institute on Drug Abuse has given a $10 million grant to a Maryland company to help it in the final phases of research regarding a possible anti-nicotine vaccine.

Nabi Biopharmaceuticals of Rockville will launch a phase III study of a potential vaccine called NicVAX. The study, which could be the last step of research if the vaccine works, represents the most advanced investigation of a smoking-cessation vaccine.

The vaccine is designed to help people quit smoking and not relapse. According to a statement by institute director Dr. Nora D. Volkow, the vaccine has received "fast track" designation from the U.S. Food and Drug Administration and has survived a successful "proof-of-concept" study.

There's no guarantee that the study will prove that the vaccine works, nor is it clear whether it will get federal approval if it does. But researchers are hopeful.

The vaccine works by making the immune system kick into action when it detects nicotine. The idea is that antibodies will bond to nicotine molecules and prevent them from entering the brain, where they give smokers the high that they crave.

Study results are preliminary so far, but they suggest that smokers who develop high levels of the antibodies in their bodies are most likely to quit for good. Researchers reported few side effects.

They expect that the vaccine will be effective for six to 12 months after it is given.

In the United States, tobacco use is linked to 400,000 deaths a year, according to background information.

More information

For more statistics about smoking, visit the American Heart Association.

-- Randy Dotinga

SOURCE: National Institute on Drug Abuse, news release, Sept. 29, 2009

Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Lucky Quitters to Receive Big Money in Stop-Smoking Contest
2. Blue Cross Stop-Smoking Program Achieves All-Time High Quit Rate
3. Stop-Smoking Therapies Have Benefits, Risks for Pregnant Women
4. NIAID announces vaccine adjuvant discovery contracts
5. Stem Cell Research Offers Hope for Colon Cancer Vaccine
6. Sebelius Urges Americans to Get Swine Flu Vaccine
7. Health Department Announces First Doses of H1N1 Vaccine Arrive in Pennsylvania
8. Seasonal Flu Vaccine May Lessen Swine Flu Impact
9. Officials Stress Safety as Swine Flu Vaccine Arrives
10. AARP Encourages All Adults 50+ to Get Flu Vaccine This Season
11. Cocaine Addiction Vaccine Shows Some Success
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... For many X-rays taken ... for accurate interpretation by the radiologist. The marking utensils are so small, however, ... has found a way to alleviate this problem. , He developed the patent-pending ...
(Date:12/1/2015)... ... December 01, 2015 , ... Visage accelerates ... a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), has announced they ... Society of North America (RSNA) 2015 annual meeting through December 3 in Chicago, ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next ... selected as a finalist in this year’s Fierce Innovation Awards: Healthcare Edition, an ... was recognized as a finalist in the category of Digital Solutions for its ...
(Date:12/1/2015)... ... ... Lutronic, a leading innovator of aesthetic and medical laser and energy-based technology, announced ... the United States. Clarity is a Superior Dual Wavelength Platform which combines two ... platform that is easy to own and operate. , For over a decade, ...
(Date:12/1/2015)... ... December 01, 2015 , ... PYA’s ... Post-Affiliation Integration ,” addresses a main “pain point” for merging or aligning healthcare ... once a deal is signed. This quick-read guidance suggests that failing to ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 01, 2015 ... addition of the "2016 Europe ... E. Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, ... their offering. --> ... the "2016 Europe Enteric Disease ...
(Date:12/1/2015)... -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing ... that the company will present at the LD Micro Main ... Luxe Sunset Boulevard Hotel in Los Angeles, CA. ... will present on Thursday, December 3, at 9:00 am Pacific ... register at least 10 minutes prior to the start of ...
(Date:12/1/2015)... CytRx Corporation (NASDAQ: CYTR ), a ... announced that it has reached its enrollment target of ... clinical trial of aldoxorubicin in patients with previously treated ... completed in Q1 2016. The Phase 3 trial is a ... Assessment from the FDA at 79 sites in ...
Breaking Medicine Technology: